Company: KROS
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001104659-25-050245
Chunk: 6

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 6
---
 regarding matters that are
not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,”
“potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of
these forward-looking statements include statements concerning the intended benefits and outcome of the strategic review process (including
timing of announcing an update), expected cash runway, expected development and regulatory pathway, timing of data release and therapeutic
benefits of the Company’s product candidates, and our continued collaboration with Takeda Pharmaceuticals. Because such statements
are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
These risks and uncertainties include, among others: whether the objectives of the strategic alternative review process will be achieved;
the terms, structure, benefits and costs of any strategic transaction; the timing of any transaction and whether any transaction will
be consummated at all; the risk that the strategic alternatives review and its announcement could have an adverse effect on the ability
of the Company to retain and hire key personnel and maintain relationships with partners, suppliers, employees, stockholders and other
business relationships and on its operating results and business generally; the risk the strategic alternatives review could divert the
attention and time of the Company’s management; the risk of any unexpected costs or expenses resulting from the review; the risk
of any litigation relating to the review; Keros’ limited operating history and historical losses; Keros’ ability to raise
additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success
of its product candidates, cibotercept, KER-065 and elritercept; that Keros may be delayed in initiating, enrolling or completing any
clinical trials; competition from third parties that are developing products for similar uses; the risk that circumstances surrounding
or leading up to our 2025 Annual Meeting may change; Keros’ ability to obtain, maintain and protect its intellectual property; and
Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in Keros’ filings
with the SEC, including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC
on May 6, 2025, and its other